drugset / Trial / NCT05562024
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
Phase 1
Recruiting
24 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Shandong Cancer Hospital and Institute · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase I clinical trials are designed as open-label, dose-escalation and dose-expansion clinical studies, the main purpose of which is to explore the tolerability, safety, cytokinetic characteristics and RP2D and preliminary observation of the efficacy of the study drug in subjects with B7-H3-positive relapsed/refractory neuroblastoma.
Timeline
- Start
- 2022-12-30
- Primary completion
- 2025-12-18
- Completion
- 2039-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | T cell injection targeting B7-H3 chimeric antigen receptor | Unknown | 2e+06 cells/kg | — |
| Subject | T cell injection targeting B7-H3 chimeric antigen receptor | Unknown | 4e+06 cells/kg | — |
| Subject | T cell injection targeting B7-H3 chimeric antigen receptor | Unknown | 8e+06 cells/kg | — |
Indications
No indication recorded.